Found: 101
Select item for more details and to access through your institution.
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Human leukocyte antigen- G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma.
- Published in:
- Genes, Chromosomes & Cancer, 2015, v. 54, n. 3, p. 185, doi. 10.1002/gcc.22235
- By:
- Publication type:
- Article
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia.
- Published in:
- Genes, Chromosomes & Cancer, 2013, v. 52, n. 3, p. 287, doi. 10.1002/gcc.22028
- By:
- Publication type:
- Article
Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case‐control study.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 9, p. E238, doi. 10.1002/ajh.25209
- By:
- Publication type:
- Article
Midostaurin in the treatment of a patient with acute myeloid leukaemia with FLT3-TKD mutation and NPM1 mutation.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 37, doi. 10.5603/HCP.2022.0006
- By:
- Publication type:
- Article
Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 23, doi. 10.5603/HCP.2022.0004
- By:
- Publication type:
- Article
A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.781364
- By:
- Publication type:
- Article
SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 11, p. 1, doi. 10.1038/s41419-020-03156-8
- By:
- Publication type:
- Article
Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 1, p. 59, doi. 10.1111/ejh.13337
- By:
- Publication type:
- Article
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real‐world” study: Polish Myeloma Group experience.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 3, p. 354, doi. 10.1111/ejh.13106
- By:
- Publication type:
- Article
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases.
- Published in:
- Molecules, 2009, v. 14, n. 3, p. 1183, doi. 10.3390/molecules14031183
- By:
- Publication type:
- Article
Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 23, p. 6048, doi. 10.3390/ijms20236048
- By:
- Publication type:
- Article
Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 4, p. 843, doi. 10.3390/ijms20040843
- By:
- Publication type:
- Article
Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 4, p. 201, doi. 10.1159/000523921
- By:
- Publication type:
- Article
Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis.
- Published in:
- Chemotherapy (0009-3157), 2014, v. 59, n. 4, p. 280, doi. 10.1159/000357468
- By:
- Publication type:
- Article
IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
- By:
- Publication type:
- Article
HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S371, doi. 10.1016/S2152-2650(21)01849-8
- By:
- Publication type:
- Article
MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S364, doi. 10.1016/S2152-2650(21)01836-X
- By:
- Publication type:
- Article
CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
- By:
- Publication type:
- Article
Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
- By:
- Publication type:
- Article
Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S236, doi. 10.1016/S2152-2650(21)01485-3
- By:
- Publication type:
- Article
Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01456-7
- By:
- Publication type:
- Article
Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
- By:
- Publication type:
- Article
Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
- By:
- Publication type:
- Article
Hematological Malignancies in the Polish Population: What are the Predictors of Outcome in Patients Admitted to Intensive Care Unit?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S219, doi. 10.1016/j.clml.2019.07.093
- By:
- Publication type:
- Article
Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2016, v. 64, p. 137, doi. 10.1007/s00005-016-0430-x
- By:
- Publication type:
- Article
HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2016, v. 64, n. 3, p. 225, doi. 10.1007/s00005-015-0372-8
- By:
- Publication type:
- Article
Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2013, v. 61, n. 2, p. 165, doi. 10.1007/s00005-012-0215-9
- By:
- Publication type:
- Article
Serum Tumor Necrosis Factor-α and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2012, v. 60, n. 6, p. 477, doi. 10.1007/s00005-012-0197-7
- By:
- Publication type:
- Article
Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2010, v. 58, n. 2, p. 131, doi. 10.1007/s00005-010-0066-1
- By:
- Publication type:
- Article
HODGKIN'S LYMPHOMA MIMICKING TUBERCULOSIS IN CERVICAL LYMPH NODES.
- Published in:
- Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists, 2014, v. 65, n. 1, p. 83, doi. 10.5114/pjp.2014.42676 P
- By:
- Publication type:
- Article
QUIZ WHAT IS YOUR DIAGNOSIS?
- Published in:
- Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists, 2013, v. 64, n. 4, p. 322, doi. 10.5114/PJP.2013.39829
- By:
- Publication type:
- Article
Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma.
- Published in:
- Journal of Clinical Immunology, 2007, v. 27, n. 3, p. 339
- By:
- Publication type:
- Article
Targeting the thioredoxin system as a novel strategy against B‐cell acute lymphoblastic leukemia.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 5, p. 1180, doi. 10.1002/1878-0261.12476
- By:
- Publication type:
- Article
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 2, p. 811, doi. 10.1007/s00432-021-03847-5
- By:
- Publication type:
- Article
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 5, p. 1563, doi. 10.1007/s10238-022-00878-1
- By:
- Publication type:
- Article
Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation.
- Published in:
- Clinical & Experimental Hepatology, 2019, v. 5, n. 3, p. 195, doi. 10.5114/ceh.2019.87631
- By:
- Publication type:
- Article
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3 A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 2, p. 181, doi. 10.1111/ejh.12566
- By:
- Publication type:
- Article
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
- Published in:
- European Journal of Haematology, 2001, v. 66, n. 3, p. 188, doi. 10.1034/j.1600-0609.2001.00303.x
- By:
- Publication type:
- Article
Influence of gemcitabine (2′,2′‐difluoro‐deoxycytidine) and 2‐chlorodeoxyadenosine on growth of normal and leukemic cellsin vitro.
- Published in:
- European Journal of Haematology, 2000, v. 65, n. 5, p. 317, doi. 10.1034/j.1600-0609.2000.065005317.x
- By:
- Publication type:
- Article
Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab-associated anaphylaxis.
- Published in:
- Polish Archives of Internal Medicine, 2018, v. 128, n. 7/8, p. 494
- By:
- Publication type:
- Article
Real-life experience with bortezomib-based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study.
- Published in:
- Polish Archives of Internal Medicine, 2017, v. 127, n. 11, p. 765, doi. 10.20452/pamw.4099
- By:
- Publication type:
- Article
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 4, p. 618, doi. 10.1111/bjh.14464
- By:
- Publication type:
- Article
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment.
- Published in:
- Cellular & Molecular Biology Letters, 2009, v. 14, n. 2, p. 248, doi. 10.2478/s11658-008-0048-z
- By:
- Publication type:
- Article
Randomized Comparison of Cladribine Alone or in Combination With Cyclophosphamide, and Cyclophosphamide, Vincristine and Prednisone in Previously Untreated Low-Grade B-Cell Non-Hodgkin Lymphoma Patients: Final Report of the Polish Lymphoma Research Group.
- Published in:
- Cancer (0008543X), 2008, v. 113, n. 2, p. 367, doi. 10.1002/cncr.23558
- By:
- Publication type:
- Article
Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing.
- Published in:
- Biomedicines, 2022, v. 10, n. 7, p. N.PAG, doi. 10.3390/biomedicines10071674
- By:
- Publication type:
- Article
International cooperation to secure access of patients in Ukraine to cellular therapies in conditions of Russian aggression.
- Published in:
- Acta Haematologica Polonica, 2024, v. 55, n. 3, p. 168, doi. 10.5603/ahp.100231
- By:
- Publication type:
- Article
Recommendations of Polish HCV Expert Group and Polish Society of Haematologists and Transfusiologists on diagnosis and treatment of HCV-infected hemato-oncology patients.
- Published in:
- Acta Haematologica Polonica, 2024, v. 55, n. 1, p. 2, doi. 10.5603/ahp.97936
- By:
- Publication type:
- Article
CLI120-001 phase1B dose escalation study of RVU120 in patients with AML or high risk MDS -- safety and efficacy data update.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 71
- By:
- Publication type:
- Article